San Diego-based mostly Viking Therapeutics marked by itself as a serious competitor in the weight loss drug sector in February soon after revealing promising facts from the mid-stage demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when supplied being a weekly injection and in March the company